-
Merck to Discontinue Parkinson’s Drug Program Targeting the Brain Chemical Adenosine
May 24, 2013
… called glutamate, which when perturbed is thought to cause dyskinesias, was also inhibited through by this drug. In … for Parkinson’s patients, while at the same time reducing dyskinesias. But today’s results, culled from three … if A2A antagonists might work to prevent, or lessen, dyskinesias. And certain research focusing on the positive …
-
What the Scientists Are Talking About
May 7, 2014
… of levodopa (called duodopa) reported 1.7 fewer hours of dyskinesia a day compared to the standard, oral medication. … for review. Takeaway: Duodopa may help avoid some dyskinesia, a debilitating side effect of the current gold … release capsules of amantadine , a medication used to treat dyskinesia. Time “on” with troublesome dyskinesia was …
-
Progress Is Tangible and Next Steps Are Worth Driving Forward
October 3, 2012
… , I discussed some exciting potential treatments for dyskinesia — involuntary movements that are a side effect of … the pipeline for novel, non-dopamine-based therapies for dyskinesia is strong — perhaps the strongest ever. A significant breakthrough for dyskinesia treatments may be on the horizon: Addex …
-
First Look: 'The Michael J. Fox Show' Airs on NBC Thursday Nights this Fall [VIDEO]
May 13, 2013
… had Parkinson's and took Parkinson's medications that had dyskinesias, that it worked effectively on a large amount of … So it eventually got repurposed...well now I have less dyskinesia and don't get the flu. So that's kinda nice. What …
-
Related Conditions
… Parkinson’s or taking levodopa for many years. Read More Dyskinesia Dyskinesia is uncontrolled, involuntary movement that can look like fidgeting or wriggling. In Parkinson's, dyskinesia can happen with long-term levodopa use and longer …
-
New Formulation of Parkinson’s Drug at FDA for Potential Approval
September 6, 2022
… feel less effective or contribute to involuntary movement (dyskinesia). ( Read more about levodopa .) A new formulation … with poor symptom control (motor fluctuations) and/or dyskinesia. When taking IPX203, volunteers had one-half hour more time without symptoms (“on” time) and without dyskinesia than they had on immediate-release …